Biotech Values

[DewDiligence]

US Supreme Court leaves ABT’s Humira victory intact:

http://online.wsj.com/article/SB10001424052970204909104577237153181498074.html

Last February, a federal appeals court threw out a 2009 jury verdict that ordered Abbott to pay $1.67 billion in damages because its arthritis therapy Humira allegedly infringed a patent co-owned by J&J unit Centocor Ortho Biotech, now known as Janssen Biotech, and New York University. The appeals court ruling, which removed a major legal cloud hanging over Abbott, said Centocor's patent claims were invalid because they lacked adequate written descriptions.

The Supreme Court let the lower court ruling stand, rejecting Janssen's [JNJ’s] appeal without comment.